Search

Only palliative therapeutic options exist for the treatment of Alzheimer’s Disease, no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involved in the aetiology of Alzheimer’s Disease, for example, amyloid peptide production and clearance, tau phosphorylation, inflammation and oxidative stress. Despite the therapeutic potential of heparin as a multi-target drug for Alzheimer’s disease, the repurposing of pharmaceutical heparin is proscribed owing to the potent anticoagulant activity of this drug. Here, a heterogenous non-anticoagulant glycosaminoglycan extract, obtained from the shrimp Litopenaeus vannamei, was found to inhibit the key neuronal β-secretase, BACE1, displaying a more favorable therapeutic ratio compared to pharmaceutical heparin when anticoagulant activity is considered.

Heparin is a vital pharmaceutical anticoagulant drug and remains one of the few naturally sourced pharmaceutical agents used clinically. Heparin possesses a structural order with up to four levels of complexity. These levels are subject to change based on the animal or even tissue sources that they are extracted from, while higher levels are believed to be entirely dynamic and a product of their surrounding environments, including bound proteins and associated cations. In 2008, heparin sources were subject to a major contamination with a deadly compound—an over-sulphated chondroitin sulphate polysaccharide—that resulted in excess of 100 deaths within North America alone. In consideration of this, an arsenal of methods to screen for heparin contamination have been applied, based primarily on the detection of over-sulphated chondroitin sulphate. The targeted nature of these screening methods, for this specific contaminant, may leave contamination by other entities poorly protected against, but novel approaches, including library-based chemometric analysis in concert with a variety of spectroscopic methods, could be of great importance in combating future, potential threats.

Production of the major anticoagulant drug, heparin, is a complex process that begins with the collection of crude material from a dispersed network of suppliers with poor traceability, an issue that was made apparent in 2007-2008, when batches of heparin were contaminated deliberately in the supply chain, resulting in over 100 deaths in the US alone. Several analytical techniques are used currently for the characterisation of pharmaceutical grade heparin, but few have been applied to its crude counterpart. One exception is NMR spectroscopy which was used to study crude heparin (2017), however, owing to the high set-up and running costs, as well as the need for skilled technical operators, the use of NMR at crude heparin production plants is unviable. An alternative, practical, spectroscopic method is attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) that is user-friendly, economical and, importantly, requires little specialised training or sample preparation. Using a top-down chemometric approach employing principal component analysis, ATR-FTIR spectroscopy was able to distinguish crude heparins based on their similarity to pharmaceutical heparin, as well as on their compositional and structural features, which included levels of sulphation, the extent of related conformational changes, as well as the quantities of chondroitin and dermatan sulphate present. This approach lends itself to automation and will enable users and regulators to undertake quality control of crude heparin during manufacture. The method requires only economical, portable equipment and little specialised training, bringing the high-quality analysis of crude heparin within reach of both manufacturers and regulators for the first time.

The widely used anticoagulant pharmaceutical, heparin, is a polydisperse, heterogeneous polysaccharide. Heparin is one of the essential medicines defined by the World Health Organisation but, during 2007-2008, was the subject of adulteration. The intrinsic heterogeneity and variability of heparin makes it a challenge to monitor its purity by conventional means. This has led to the adoption of alternative approaches for its analysis and quality control, some of which are based on multivariate analysis of 1H NMR spectra, or exploit correlation techniques. Such NMR spectroscopy-based analyses, however, require costly and technically demanding NMR instrumentation. Here, an alternative approach based on the use of attenuated total reflectance Fourier transform infrared spectroscopy (FTIR-ATR) combined with multivariate analysis is proposed. FTIR-ATR employs more affordable and easy-to-use technology and, when combined with multivariate analysis of the resultant spectra, readily differentiates between glycosaminoglycans of different types, between heparin samples of distinct animal origins and enables the detection of both known heparin contaminants, such as over-sulphated chondroitin sulfate (OSCS), as well as other alien sulphated polysaccharides in heparin samples to a degree of sensitivity comparable to that achievable by NMR. The approach will permit the rapid and cost-effective monitoring of pharmaceutical heparin at any stage of the production process and indeed, in principle, the quality control of any heterogeneous or variable material.

Despite recent successful control efforts, malaria remains a leading global health burden. Alarmingly, resistance to current antimalarials is increasing and the development of new drug families is needed to maintain malaria control. Current antimalarials target the intraerythrocytic developmental stage of the Plasmodium falciparum life cycle. However, the invasive extracellular parasite form, the merozoite, is also an attractive target for drug development. We have previously demonstrated that heparin-like molecules, including those with low molecular weights and low anticoagulant activities, are potent and specific inhibitors of merozoite invasion and blood-stage replication. Here we tested a large panel of heparin-like molecules and sulfated polysaccharides together with various modified chemical forms for their inhibitory activity against P. falciparum merozoite invasion. We identified chemical modifications that improve inhibitory activity and identified several additional sulfated polysaccharides with strong inhibitory activity. These studies have important implications for the further development of heparin-like molecules as antimalarial drugs and for understanding merozoite invasion.

Therapeutic options for Alzheimer&rsquo, s disease, the most common form of dementia, are currently restricted to palliative treatments. The glycosaminoglycan heparin, widely used as a clinical anticoagulant, has previously been shown to inhibit the Alzheimer&rsquo, s disease-relevant &beta, secretase 1 (BACE1). Despite this, the deployment of pharmaceutical heparin for the treatment of Alzheimer&rsquo, s disease is largely precluded by its potent anticoagulant activity. Furthermore, ongoing concerns regarding the use of mammalian-sourced heparins, primarily due to prion diseases and religious beliefs hinder the deployment of alternative heparin-based therapeutics. A marine-derived, heparan sulphate-containing glycosaminoglycan extract, isolated from the crab Portunus pelagicus, was identified to inhibit human BACE1 with comparable bioactivity to that of mammalian heparin (IC50 = 1.85 &mu, g mL&minus, 1 (R2 = 0.94) and 2.43 &mu, 1 (R2 = 0.93), respectively), while possessing highly attenuated anticoagulant activities. The results from several structural techniques suggest that the interactions between BACE1 and the extract from P. pelagicus are complex and distinct from those of heparin.